Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: yang t, yang xm, yang yk, yang ss, yang m. Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2. Signal Transduct Target Ther. 2022. PMID: 35665745 Free PMC article. Clinical Trial.
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
Qiu J, Yang Y, Huang L, Wang L, Jiang Z, Gong J, Wang W, Wang H, Guo S, Li C, Wei S, Mo Z, Xia J. Qiu J, et al. Hum Vaccin Immunother. 2017 Jun 3;13(6):1-10. doi: 10.1080/21645515.2017.1288769. Epub 2017 Mar 1. Hum Vaccin Immunother. 2017. PMID: 28362135 Free PMC article. Clinical Trial.
Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.
Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, Zhang Z, Sun L, Chen X, Yang Y, Shi X, Guo Y, Sun Y, Li H, Li N, Han S, Ma M, Yang X. Yan S, et al. Vaccine. 2020 Sep 11;38(40):6274-6279. doi: 10.1016/j.vaccine.2020.07.042. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747216 Clinical Trial.
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Xia S, et al. JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543. JAMA. 2020. PMID: 32789505 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Xia S, et al. Lancet Infect Dis. 2021 Jan;21(1):39-51. doi: 10.1016/S1473-3099(20)30831-8. Epub 2020 Oct 15. Lancet Infect Dis. 2021. PMID: 33069281 Free PMC article. Clinical Trial.
[Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use].
Yang ZN, Zhao YY, Li L, Gao HD, Cai Q, Sun XX, Zhang FS, Su JF, Zhang YN, Shu X, Wang XW, Yang YK, Zhang YT, Zhou S, Yang XM. Yang ZN, et al. Among authors: yang xm, yang yk. Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Jun 10;42(6):977-982. doi: 10.3760/cma.j.cn112338-20210325-00249. Zhonghua Liu Xing Bing Xue Za Zhi. 2021. PMID: 33874701 Chinese.
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Al Kaabi N, et al. JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565. JAMA. 2021. PMID: 34037666 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang W, Zhang W, Li N, Xie Z, Zhu X, Ding L, You W, Zhao Y, Zhao J, Huang L, Shi X, Yang Y, Xu G, Wang W, Liu P, Ma M, Qiao Y, Zhao S, Chai J, Li Q, Fu H, Xu Y, Zheng X, Guo W, Yang X. Xia S, et al. Lancet Infect Dis. 2022 Feb;22(2):196-208. doi: 10.1016/S1473-3099(21)00462-X. Epub 2021 Sep 15. Lancet Infect Dis. 2022. PMID: 34536349 Free PMC article. Clinical Trial.
The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
Al Kaabi N, Oulhaj A, Al Hosani FI, Al Mazrouei S, Najim O, Hussein SE, Abdalla JS, Fasihuddin MS, Hassan AA, Elghazali G, Al Rumaithi A, Al Azazi J, Weber S, Beiram R, Parekh KA, Sheek-Hussein M, Yang Y, Xiaoming Y, Quliang J, Eltantawy I, Mahmoud S, Koshy A, Xiao P, Ganesan S, Elamin W, Zaher W. Al Kaabi N, et al. Sci Rep. 2022 Jan 11;12(1):490. doi: 10.1038/s41598-021-04244-1. Sci Rep. 2022. PMID: 35017530 Free PMC article.
561 results